Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform
Eli Lilly's obesity lead is only the starting point. See what its pipeline, manufacturing build-out, pricing pressure, and earnings trajectory could mean for the stock's next chapter.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.